In the current study, we have demonstrated, for the first time, the function and mechanisms of AZGP1P2 in controlling the treatment resistance of docetaxel in CRPC by regulating the stemness of prostate cancer stem cells (PCSCs). This evidence concerns the gene AZGP1P2 and prostate cancer.